A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01171651
Recruitment Status : Completed
First Posted : July 28, 2010
Last Update Posted : January 20, 2016
Information provided by (Responsible Party):
SillaJen, Inc. ( Jennerex Biotherapeutics )

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : February 2013
  Study Completion Date : December 2015